



RECEIVED

OCT 19 2000

COLLY COMPA

TECHTEMER DECOMES THE TECHTO TO THE TECHTOR TO THE TECHTO TO THE TECHTOR THE TECHTOR TO THE TECHTOR TH

Certificate of Mailing: Date of Deposit: Oct	tober 12, 2000
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is Service as first class mail with sufficient postage on the date indica Commissioner for Patents, Washington, D.C. 20231. Susan M. Barry	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Dolorès Ludevid et al.

Art Unit:

1638

Serial No.:

09/117,246

Examiner:

Zaghmout, O.

Filed:

December 3, 1998

Title:

AMINO ACID-ENRICHED PLANT PROTEIN RESERVES,

PARTICULARLY LYSINE-ENRICHED MAIZE γ-ZEIN, AND

PLANTS EXPRESSING SUCH PROTEINS

Assistant Commissioner For Patents Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.821

As part of the patent application filed on December 3, 1998, enclosed is a sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of eight pages.

As required by 37 CFR 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney.

Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.



RECEIVED

OCT 19 2000

CFR §1.821(d), the sequence identifiers are used throughout the

TECH CENTER 1500/2900 application description and claims to refer to their respective sequences.

As required by 37 CFR 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 CFR §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 CFR §1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

ristina Bieker-Brady, Ph.D.

Reg. No. 30,109

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

\\Ntserver\documents\50062\50062.004001 Seq. Statement.wpd

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING Application No.: 09/117,246 NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not followir ie

llowing reason(s):
UT 1 6 2000 ≦
1. This application clearly fails to compley ith the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support (SIRA)
recnnical Assistance
To Purchase Patentin Software703-306-2600
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE